Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of CSL222 gene therapy in adults with severe or moderately severe hemophilia B
NL-OMON52495Phase 3Recruiting
- Sponsor
- CSL Behring
- Start
- Feb 2019
- Modality
- Gene Therapies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of etranacogene dezaparvovec in hemophilia B (HB), sponsored by CSL Behring. Primary endpoint: Annualized bleeding rate non-inferiority comparison. Started Feb 2019; status: recruiting.
02
Drugs
etranacogene dezaparvovec
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on NL-OMON52495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52495.